CHHiP (Conventional or Hypofractionated High Dose IMRT for Prostate Cancer)

CHHiP is a randomised phase 3, non-inferiority trial recruiting men with localised prostate cancer (pT1b-T3aN0M0). Patients were randomly assigned (1:1:1) to conventional (74 Gray (Gy) delivered in 37 fractions (f) over 7.4 weeks) or one of two hypofractionated schedules (60Gy/20f over 4 weeks or 57Gy/19f over 3.8 weeks) all delivered with intensity modulated techniques. The primary endpoint was time to biochemical/clinical failure; critical hazard ratio (HR) for non-inferiority was 1.208. The CHHiP trial is registered (ISRCTN97182923). From Oct 18, 2002 to June 17, 2011, 3216 men were recruited from 71 centres (74Gy: 1065, 60Gy: 1074, 57Gy: 1077). Median follow-up is 62.4 months (IQR 53.9-77.0). The proportion of patients biochemical/clinical failure-free at 5 years was 74Gy: 88.3% (95%CI 86.0-90.2), 60Gy: 90.6% (88.5-92.3), 57Gy: 85.9% (83.4-88.0). 60Gy was shown to be non-inferior to 74Gy: HR 0.84 (90%CI: 0.68-1.03) but non-inferiority could not be claimed for 57Gy: HR 1.20 (0.99-1.46). The α/β ratio for prostate cancer was estimated at 1.8Gy. There were similar long-term side-effects in all treatment groups with no significant difference in the proportion of patients reporting a RTOG grade 2 or worse bowel/bladder toxicity at 5 years (74Gy: 1.3%/1.7%, 60Gy: 2.3%/1.8%, p=0.26/p=1.00, 57Gy: 2.0%/1.8%, p=0.48/p=1.00). Hypofractionated radiotherapy using 60Gy/20f is non-inferior to conventional fractionation using 74Gy/37f and is recommended as a new standard of care.

Existing samples:

  • Malignant tumor of prostate (disorder)

Bespoke collection capabilities:

  • Carcinoma in situ of prostate

Contact Information


The Institute of Cancer Research
15 Cotswold Road

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A